Article
[The treatment of hepatitis C].
Nederlands tijdschrift voor geneeskunde - 21 Jun 2003
Orlent H, Vrolijk J M, de Man R A, Schalm S W
Abstract excerpt
The recent advances in the antiviral therapy of hepatitis C have significantly lowered the threshold for offering such therapy to patients. Sustained virological response rates of 42-46% are achieved after 48 weeks of combination therapy with peginterferon alpha and ribavirin in patients with genotype 1 infection. In patients with a genotype 2 or 3 infection, 24 weeks of combination therapy leads to a sustained...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.